Evidence map›Paper›PMID 20738419›Full record

ArticleImmunology2011

Interplay of T-cell receptor and interleukin-2 signalling in Vγ2Vδ2 T-cell cytotoxicity.

Haishan Li, C David Pauza

Open access · greenAbstract read
In one paragraph

Article in Immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Apoptosis InducedFrontiers in immunology · 2017
    Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Haishan LiInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
C David Pauza
University of Maryland, Baltimore · US

Funding

Mechanisms for depleting tumor immunity in AIDSR01CA142458 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI PAUZA, C. DAVID · 2009 to 2012
$1.6M
NCI NIH HHS CA142458NCI NIH HHS R01 CA142458
6 · The paper itself

Abstract

Human peripheral blood Vγ2Vδ2 T cells are important for host defence and tumour immunity. Their unusual T-cell receptor (TCR) recognizes small molecule phosphoantigens; stimulated cells produce inflammatory cytokines and are potently cytotoxic for a variety of tumours. However, molecular mechanisms linking phosphoantigen stimulation and cytotoxicity are incompletely understood. We know that isopentenyl pyrophosphate (IPP) activates mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/Erk) and phosphoinositide 3-kinase (PI-3K)/Akt pathways; specific inhibition of Erk or Akt significantly impairs the functional response to IPP. We now show that interleukin-2 also activates MEK/Erk and PI-3K/Akt pathways but on its own, fails to induce cytokine expression or cytotoxicity. Hence, MEK/Erk and PI-3K/Akt activation are necessary but not sufficient to induce effector responses in Vγ2Vδ2 T cells and a TCR-dependent signal is still required for tumour cell killing. Cyclosporin A, an inhibitor of calcineurin, blocked calcium-dependent nuclear translocation of nuclear factor of activated T cell (NFAT) and significantly reduced IPP-induced cytokine production, degranulation and cytotoxicity. The IPP-induced calcium mobilization and NFAT translocation were necessary to activate Vγ2Vδ2 effector functions; interleukin-2, acting on the MEK/Erk pathway, regulated the strength of these responses. The TCR has a specific role in Vγ2Vδ2 T-cell killing of tumour cells, which is distinct from its role in triggering cellular proliferation in response to phosphoantigens.

Indexed as

Cytotoxicity, ImmunologicAntineoplastic AgentsCell ProliferationCyclosporineCytokinesDose-Response Relationship, DrugDrug Screening Assays, AntitumorExtracellular Signal-Regulated MAP KinasesHemiterpenesHumansInterleukin-2Organophosphorus CompoundsPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsPhosphorylationReceptors, Antigen, T-Cell, gamma-deltaAntineoplastic AgentsCyclosporineCytokinesExtracellular Signal-Regulated MAP KinasesHemiterpenesInterleukin-2isopentenyl pyrophosphateOrganophosphorus CompoundsPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsReceptors, Antigen, T-Cell, gamma-delta

Identifiers

PMID20738419
PMCPMC3015079
OpenAlexW1495173463

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.